Today, at HPA Gambelas, one of the first patients (nationally) started innovative immunotherapy for advanced bladder cancer, capable of reducing the risk of mortality by 31%.
According to oncologist Dr. André Andraz Cruz ""treatment with immunotherapy in advanced bladder cancer has been a reality since 2017. However, it was only recommended in some patients (in 1st line if PD-L1 positive or 2nd line after chemotherapy failure ). Based on the Javelin-100 study, the European Medicines Agency approved the drug Avelumab (Bavencio®) on 25th January 2021 for all patients who respond to initial chemotherapy. This recent immunotherapy treatment, considered maintenance, increases overall survival, decreasing the risk of death by 31%. These are very encouraging results in this disease and the Oncology Unit of the Gambelas Unit is pleased to have started its first treatment today, one of the pioneers on a national level.
26th February 202126, February 2021